Baddi, Himachal Pradesh, India: Theon Pharma today announced the launch of India’s first Vonoprazan–Amoxicillin–Clarithromycin Triple Therapy Kit, following approval from the Central Drugs Standard Control Organisation (CDSCO). With this milestone, Theon becomes the first pharmaceutical company in India to introduce a ready-to-use, co-packaged Potassium-Competitive Acid Blocker (PCAB)-based triple therapy kit for the eradication of Helicobacter pylori (H. pylori) infection and the treatment of associated peptic ulcer disease in adult patients.
The launch represents a significant advancement in India’s gastroenterology segment by bringing an internationally accepted treatment approach to Indian healthcare professionals and patients. Designed to provide a complete 14-day treatment regimen in a convenient co-packaged format, the kit combines Vonoprazan, Amoxicillin, and Clarithromycin, enabling simplified prescribing, improved patient compliance, and better clinical outcomes.
Globally, Vonoprazan-based triple therapy has emerged as an important advancement in H. pylori eradication due to its rapid, potent, and sustained acid suppression, which enhances antibiotic effectiveness and contributes to higher eradication rates compared with conventional proton pump inhibitor (PPI)-based regimens.
Addressing a Significant Clinical Challenge
Helicobacter pylori infection remains one of the most prevalent chronic bacterial infections worldwide and continues to be a major public health concern in India. The bacterium is a leading cause of chronic gastritis, gastric and duodenal ulcers, dyspepsia, and mucosa-associated lymphoid tissue (MALT) lymphoma, while also significantly increasing the long-term risk of gastric cancer if left untreated.
According to a comprehensive 2025 meta-analysis covering 52 studies across 15 Indian states, the pooled prevalence of H. pylori infection was reported to be 54% among patients with gastrointestinal diseases and 61% among individuals without clinically diagnosed gastrointestinal disorders, highlighting the widespread burden of infection across the country.
Over the past decade, increasing antimicrobial resistance, declining effectiveness of traditional PPI-based eradication therapies, and inconsistent patient adherence have created an urgent need for more effective and standardized treatment options. Healthcare professionals are increasingly seeking therapeutic approaches that offer stronger acid suppression, improved antibiotic activity, and simplified treatment regimens.
By introducing India’s first PCAB-based triple therapy kit, Theon Pharma aims to support clinicians with a guideline-aligned treatment option that addresses these evolving clinical needs while improving eradication success and enhancing the overall patient experience.
A New Standard in H. pylori Therapy
The Vonoprazan–Amoxicillin–Clarithromycin Kit combines three well-established medicines in a single co-packaged treatment designed for twice-daily administration over 14 days.
Unlike conventional proton pump inhibitors, Vonoprazan is a next-generation Potassium-Competitive Acid Blocker (PCAB) that delivers rapid onset, potent acid suppression, and sustained gastric pH control. Maintaining a consistently higher gastric pH creates an optimal environment for antibiotics such as amoxicillin and clarithromycin to exert their antibacterial activity against H. pylori, ultimately improving treatment effectiveness.
The CDSCO has approved Vonoprazan tablets (10 mg and 20 mg) in India for multiple acid-related disorders, including reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of combination therapy for H. pylori eradication.
Internationally, Vonoprazan-based triple therapy has become an established treatment option and is increasingly incorporated into clinical practice because of its favorable eradication outcomes and patient-friendly dosing schedule.
The co-packaged presentation also minimizes dispensing errors, simplifies treatment initiation, and encourages better adherence by providing patients with the complete therapy in a single, easy-to-use pack.
Strengthening India’s Access to Advanced Therapies
As the first company to commercialize this innovative triple therapy kit in India, Theon Pharma continues to demonstrate its commitment to introducing globally relevant pharmaceutical innovations that address unmet medical needs.
The launch reflects the company’s broader strategy of expanding access to advanced, evidence-based therapies while supporting physicians with treatment solutions that align with evolving international clinical practices.
Backed by world-class manufacturing facilities, stringent quality systems, and a strong regulatory framework, Theon Pharma continues to strengthen its position as a trusted pharmaceutical partner for healthcare professionals across India and international markets.
The company remains focused on developing differentiated products that improve therapeutic outcomes while ensuring the highest standards of quality, safety, and regulatory compliance.
Leadership Perspective:
Commenting on the launch, Mr. Amit Bansal, Managing Director, Theon Pharma, said:
“At Theon Pharma, our vision is to continuously bring globally relevant pharmaceutical innovations to Indian patients through quality, science, and accessibility. The launch of India’s first Vonoprazan–Amoxicillin–Clarithromycin Triple Therapy Kit reflects our commitment to addressing unmet medical needs with differentiated, evidence-based solutions. This milestone not only reinforces our leadership in introducing advanced therapies but also underscores our dedication to strengthening India’s healthcare ecosystem through innovation, world-class manufacturing, and a patient-centric approach.”
Mr. Punit Bansal, Director, Theon Pharma, said:
“Helicobacter pylori infection continues to pose a significant healthcare burden in India, with millions of patients at risk of chronic gastrointestinal diseases and their long-term complications. As the first company to introduce a Vonoprazan–Amoxicillin–Clarithromycin Triple Therapy Kit in India, we are proud to bring a globally recognized, next-generation treatment option to Indian physicians and patients. This launch reflects our commitment to innovation, quality, and improving patient outcomes through evidence-based therapies. We believe this convenient, PCAB-based co-packaged regimen will help simplify treatment, improve adherence, and support better eradication success across diverse patient populations.”
Disclaimer: The above content is non-editorial, and TIL hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
